Eisai Company, Limited

Ucb S.a.

Ucb, S.a./n.v.

Eric Schwartz

Dong Zou

Hai-Xiao Zhai

Jeremy Kintigh

Rama Kondru

Olivier Dasse

Laurent Knerr

Janelle Evans

Paul Higgins

Michael D Lewis

Hu Yang

James J Kowalczyk

Ana Maria Garcia

The present invention provides pharmaceutical compositions and novel compounds useful in the treatment of conditions mediated by CCR2, MCP-1 or the interaction thereof. The compounds of the present invention are pyrrolidinones and pyrrolidine-thiones.

Pyrrolidinone derivatives

Peptidomimetic isoprenyl transferase inhibitors R6SCHR1&prime;CHR1WCHR2YC(:X)NR3CHR5COR4 wherein R1&equals;OH, H, alkyl, amino group or R1 and R6 together form a heterocyclic ring; R1&prime;&equals;H, alkyl, aryl; R2&equals;H, alkyl, arylalkyl, heteroarylalkyl; R3&equals;H, alkyl, arylalkyl; R4&equals;OH, alkoxy, amino group; R5&equals;natural amino acid residue or D&mdash;E&mdash;F, where D is alkyl or alkenyl, E is O, S, N, or null, F is H, alkyl, aryl, carboxy amino, etc.; R6&equals;H, alkyl, acyl, etc.; W&equals;alkyl, alkenyl; X&equals;O, S, Y is M&mdash;O&mdash;P, where M is C0-6 alkyl, O is oxygen-C0-4 alkyl, P is(un)substituted C6-20 aryl are disclosed.

Inhibitors of isoprenyl transferase

Growing community of inventors

Wakefield, MA, United States of America

Eric Schwartz